Sugi Predict

Sugi Predict / Compounds / SCHEMBL8941849

SCHEMBL8941849

SCHEMBL8941849

O=C(Nc1cccc(-c2c[nH]c3ncc(Cl)cc23)n1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 6/20 0.57
▸ CLK4 Q9HAZ1 5/20 0.57
▸ MAP4K4 O95819 4/20 0.57
▸ PRKD3 O94806 4/20 0.57
▸ NTRK1 P04629 4/20 0.57
▸ FLT4 P35916 4/20 0.57
▸ FLT3 P36888 4/20 0.57
▸ CLK2 P49760 4/20 0.57
▸ CAMK2B Q13554 4/20 0.57
▸ CAMK2G Q13555 4/20 0.57
▸ CAMK2D Q13557 4/20 0.57
▸ NTRK3 Q16288 4/20 0.57
▸ PKN2 Q16513 4/20 0.57
▸ PRKD2 Q9BZL6 4/20 0.57
▸ SLK Q9H2G2 4/20 0.57
▸ SGK2 Q9HBY8 4/20 0.57
▸ LCK P06239 3/20 0.57
▸ MAP4K2 Q12851 3/20 0.57
▸ PTK6 Q13882 3/20 0.57
▸ MINK1 Q8N4C8 3/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8942477 0.93 GRM5 (0.54) AXLCLK4MAP4K4PRKD3NTRK1
SCHEMBL8942516 0.90 SMN1; SMN2 (0.52) AXLCLK4MAP4K4PRKD3NTRK1
SCHEMBL8942566 0.88 CNR2 (0.52) AXLCLK4MAP4K4PRKD3NTRK1
SCHEMBL8942207 0.88 BTK (0.50) AXLCLK4MAP4K4PRKD3NTRK1
SCHEMBL8942466 0.86 BTK (0.52) AXLCLK4MAP4K4PRKD3NTRK1
SCHEMBL8942335 0.85 ROCK1 (0.55) AXLCLK4MAP4K4PRKD3NTRK1
SCHEMBL8940649 0.84 BTK (0.50) AXLCLK4MAP4K4PRKD3NTRK1
SCHEMBL8942341 0.83 BTK (0.49) AXLCLK4MAP4K4PRKD3NTRK1
SCHEMBL8940844 0.82 BTK (0.53) JAK2ITKBTKROCK1
SCHEMBL12657532 0.82 KMT2A (0.49) AXLCLK4MAP4K4PRKD3NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150152103-A1 AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2015-06-04 — — US disclosed
US-20150152103-A1 AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2015-06-04 — — US disclosed
US-8987454-B2 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-03-24 — — US disclosed
US-8987454-B2 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-03-24 — — US disclosed
US-8722889-B2 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-13 — — US disclosed
US-8722889-B2 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-05-13 — — US disclosed
US-8501446-B2 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-08-06 — — US disclosed
US-20120258958-A1 AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-11 — — US disclosed
US-20120258958-A1 AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-10-11 — — US disclosed
US-8188281-B2 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 — — US disclosed
US-8188281-B2 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 — — US disclosed
US-20090176763-A1 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2009-07-09 — — US disclosed
US-20090176763-A1 Azaindoles useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED 2009-07-09 — — US disclosed
US-7507826-B2 Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-03-24 — — US disclosed
US-7507826-B2 Such as 3-(2-Methanesulfonyl-pyrimidin-4-yl)-5-pyridin-3-yl-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridine; heart disease, diabetes, Alzheimer's disease, immunodeficiency disorders, inflammatory diseases, hypertension, allergic diseases, autoimmune diseases, destructive bone disorders VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120258958-A1 AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES JAK3, JAK2, JAK1 AXL 1252/4885CLK4 1414/4885MAP4K4 154/4885
US-20090176763-A1 Azaindoles useful as inhibitors of JAK and other protein kinases JAK3, JAK2, JAK1 AXL 1252/4885CLK4 1414/4885MAP4K4 154/4885
US-20150152103-A1 AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES JAK3, JAK2, JAK1 AXL 1252/4885CLK4 1414/4885MAP4K4 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.